Suppliers and packagers for nifedipine

nifedipine

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Acella	NIFEDIPINE	nifedipine	CAPSULE;ORAL	072781	ANDA	NuCare Pharmaceuticals,Inc.	66267-831-04	4 CAPSULE in 1 BOTTLE (66267-831-04)	2009-08-11
Heritage Pharma	NIFEDIPINE	nifedipine	CAPSULE;ORAL	202644	ANDA	Major Pharmaceuticals	0904-7229-61	100 BLISTER PACK in 1 CARTON (0904-7229-61) / 1 CAPSULE in 1 BLISTER PACK	2022-08-23
Heritage Pharma	NIFEDIPINE	nifedipine	CAPSULE;ORAL	202644	ANDA	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-194-01	100 CAPSULE in 1 BOTTLE (23155-194-01)	2010-12-07
Heritage Pharma	NIFEDIPINE	nifedipine	CAPSULE;ORAL	202644	ANDA	Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.	23155-194-13	300 CAPSULE in 1 BOTTLE (23155-194-13)	2010-12-07

Nifedipine API Manufacturing Landscape: Key Suppliers and Patent Activity

Last updated: February 19, 2026

This report analyzes the current landscape of Nifedipine Active Pharmaceutical Ingredient (API) manufacturing, focusing on key suppliers, their production capacities, and relevant patent activity. The analysis identifies established manufacturers and emerging players, providing insights into the competitive environment and potential intellectual property challenges.

Who are the primary manufacturers of Nifedipine API?

The global Nifedipine API market is characterized by a mix of established Indian and Chinese manufacturers, alongside some European entities. These suppliers vary in terms of production scale, regulatory approvals, and market reach.

• Indian Manufacturers: India is a significant hub for Nifedipine API production. Companies such as Lupin Ltd., Sun Pharmaceutical Industries Ltd., and Dr. Reddy's Laboratories Ltd. have historically played a substantial role. These firms benefit from established manufacturing infrastructure and a strong presence in both regulated and semi-regulated markets. Other notable Indian suppliers include Aarti Drugs Ltd. and Cadila Healthcare Ltd. (now Zydus Lifesciences).
• Chinese Manufacturers: China also hosts several key Nifedipine API producers. These include companies like Zhejiang Huahai Pharmaceutical Co., Ltd., and NCPC (North China Pharmaceutical Group Corporation). Chinese manufacturers often offer competitive pricing due to economies of scale and efficient production processes. Their regulatory compliance has been progressively strengthening, allowing them access to more developed markets.
• European Manufacturers: While less dominant in terms of sheer volume compared to Asian counterparts, some European companies also manufacture Nifedipine API. These often focus on niche markets or specific high-purity grades, adhering to stringent European Union Good Manufacturing Practices (GMP) standards. Examples include companies that may operate on a smaller, specialized scale.

The capacity of these manufacturers can fluctuate based on market demand and investment in new facilities. Major players often have multi-site operations, allowing for redundancy and scalability. For instance, companies like Huahai Pharmaceutical have demonstrated significant API production capacity across various therapeutic areas, which would likely extend to Nifedipine.

A comparative analysis of production scale is difficult to ascertain precisely due to proprietary information. However, based on global market share and reported revenue, companies like Sun Pharma and Lupin in India, and Huahai in China, are generally considered to be among the largest producers by volume. Their ability to supply significant quantities underpins their importance in the Nifedipine supply chain.

What is the patent landscape surrounding Nifedipine?

The patent landscape for Nifedipine is mature, with the compound itself and its basic formulations being off-patent for decades. However, innovation continues in areas such as novel salt forms, polymorphs, sustained-release formulations, and manufacturing processes.

• Early Patents: The original patents for Nifedipine, filed in the late 1960s and early 1970s, have long expired. These foundational patents were crucial in establishing Nifedipine as a commercially viable calcium channel blocker. Bayer AG was a key originator in this period.
• Process Patents: Patents related to improved manufacturing processes for Nifedipine API are still periodically filed. These often focus on increasing yield, reducing impurities, or developing more environmentally friendly synthesis routes. For example, patents might claim specific catalytic steps or purification methods that offer an advantage over existing processes.
• Polymorph Patents: Different crystalline forms (polymorphs) of an API can affect its stability, solubility, and bioavailability. Companies have sought and continue to seek patents on novel and advantageous polymorphs of Nifedipine, as well as methods for their preparation. These can offer significant intellectual property protection. For example, patent literature has revealed different crystalline forms of Nifedipine that may offer improved processing characteristics or therapeutic profiles.
• Formulation Patents: The most active area of patenting around Nifedipine has historically been in advanced drug delivery systems. This includes extended-release (ER) or sustained-release (SR) formulations designed to provide a more stable plasma concentration of the drug, reducing dosing frequency and potential side effects. Patents in this domain often cover specific matrix technologies, coating materials, or combinations of release-controlling excipients. Examples include technologies developed by companies like Purdue Pharma or Alza Corporation (now part of Johnson & Johnson), though many of these foundational formulation patents may also be nearing or have passed expiration.
• New Salt Forms and Co-crystals: While less common for older drugs, research into new salt forms or co-crystals of Nifedipine that offer improved physicochemical properties (e.g., solubility, stability) can also be patentable.

Key Patent Filers and Assignees: While specific active patents change rapidly, historical and ongoing filings indicate activity from:

• Major Pharmaceutical Companies: Originator companies and large generic manufacturers have historically filed patents related to Nifedipine formulations and manufacturing.
• Specialized Formulation Companies: Companies focused on drug delivery technologies are often key players in filing formulation patents.
• API Manufacturers: Some API manufacturers actively file patents related to novel or improved synthesis routes.

Impact of Patent Expirations: The expiration of key formulation patents, particularly for extended-release versions, has historically led to increased generic competition. This dynamic drives down prices and necessitates that manufacturers differentiate themselves through cost-efficiency, quality, or by developing next-generation formulations or API production methods.

Navigating the Patent Landscape: Companies seeking to enter or expand in the Nifedipine market must conduct thorough freedom-to-operate (FTO) analyses to ensure their manufacturing processes and intended formulations do not infringe on existing, valid patents. This involves scrutinizing patent databases for process claims, polymorph claims, and formulation claims.

What are the regulatory considerations for Nifedipine API suppliers?

Suppliers of Nifedipine API must adhere to stringent regulatory requirements to ensure product quality, safety, and efficacy. These regulations vary by region but generally encompass Good Manufacturing Practices (GMP) and detailed documentation.

• Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP guidelines. The specific GMP standards are set by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). Compliance involves rigorous quality control, robust documentation, validated manufacturing processes, and well-maintained facilities.
• Drug Master Files (DMFs): API suppliers typically submit Drug Master Files (DMFs) to regulatory agencies. A DMF is a submission to a regulatory agency that contains detailed information about the manufacturing process, facilities, and quality controls for a drug substance. This allows pharmaceutical companies using the API to reference the DMF in their drug product applications without disclosing proprietary manufacturing information to their customers.
  • Type II DMF (US): This is common for API manufacturing and contains information on facilities, processes, and quality controls.
  • CEP/COS (Europe): A Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) is issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and demonstrates that an API complies with the European Pharmacopoeia.
• Pharmacopoeial Standards: Nifedipine API must meet the specifications outlined in major pharmacopoeias, including the United States Pharmacopoeia (USP), the European Pharmacopoeia (Ph. Eur.), and the Japanese Pharmacopoeia (JP). These monographs define critical quality attributes such as purity, assay, impurity profiles, and physical characteristics.
• Impurity Profiling: Regulatory agencies require manufacturers to identify, quantify, and control impurities in the API. This includes process-related impurities, degradation products, and residual solvents. Stringent analytical methods are necessary for comprehensive impurity profiling. For Nifedipine, known impurities and potential genotoxic impurities are critical areas of focus.
• Stability Testing: API suppliers must conduct comprehensive stability studies to determine the shelf life of the Nifedipine API under various storage conditions, as per ICH guidelines (International Council for Harmonisation).
• Audits and Inspections: API manufacturing facilities are subject to regular audits by regulatory authorities and by their pharmaceutical clients. Successful audits are essential for maintaining supply agreements and market access.
• Country-Specific Regulations: Beyond international standards, suppliers must also comply with the specific regulatory requirements of the countries where the finished drug product will be marketed. This can include registration processes, import/export regulations, and local quality standards.

Key Regulatory Bodies:

• U.S. Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Pharmaceuticals and Medical Devices Agency (PMDA) - Japan
• National Medical Products Administration (NMPA) - China
• Central Drugs Standard Control Organisation (CDSCO) - India

The ability of an API supplier to consistently meet these regulatory demands is a critical differentiator in the market, influencing their ability to supply to highly regulated markets such as the U.S. and Europe.

What are the market dynamics and competitive factors for Nifedipine API?

The Nifedipine API market is largely driven by generic demand, with competition primarily centered on cost, quality, and supply chain reliability.

• Generic Competition: Nifedipine is a widely used medication, and its primary market is in generic formulations. This means that the bulk of the demand comes from pharmaceutical companies seeking cost-effective API to produce generic Nifedipine tablets and capsules.
• Price Sensitivity: Due to the high level of generic competition for finished drug products, price is a significant competitive factor for API suppliers. Manufacturers with efficient production processes and economies of scale can offer more competitive pricing. Indian and Chinese manufacturers often hold an advantage in this regard.
• Quality and Regulatory Compliance: While price is crucial, consistent high quality and robust regulatory compliance are non-negotiable. Suppliers must be able to demonstrate adherence to GMP and provide comprehensive documentation (e.g., DMFs, Certificates of Analysis) that meets the requirements of regulated markets. Failure to meet quality standards can lead to product recalls, regulatory actions, and loss of customer trust.
• Supply Chain Security and Reliability: Pharmaceutical companies rely on a consistent and uninterrupted supply of API. Disruptions can lead to drug shortages and significant financial losses. Therefore, suppliers with strong supply chain management, multiple manufacturing sites, and a proven track record of reliability are preferred. Geopolitical factors and global supply chain vulnerabilities can also influence sourcing decisions.
• Technological Advancements: While Nifedipine is an established drug, there is still scope for differentiation through improved manufacturing processes that reduce costs, enhance purity, or improve environmental sustainability. Companies that invest in process R&D can gain a competitive edge.
• Customer Relationships and Service: Strong relationships with key pharmaceutical clients, coupled with excellent customer service, including technical support and responsiveness, are important for retaining business.
• Market Access: The ability to supply to key geographical markets (e.g., North America, Europe, Japan) is a major factor. This requires meeting the specific regulatory requirements of each region and possessing the necessary certifications.

Key Competitive Factors:

1. Cost-Efficiency: Driven by large-scale production and optimized processes.
2. Quality Assurance: Consistent adherence to global GMP standards and pharmacopoeial specifications.
3. Regulatory Expertise: Successful navigation of DMF filings and regulatory inspections across multiple jurisdictions.
4. Supply Chain Resilience: Robust systems to ensure timely and uninterrupted delivery.
5. Technical Support: Providing analytical data, process insights, and troubleshooting assistance to clients.

The competitive landscape is dynamic, with new entrants and shifting market shares influenced by pricing pressures, regulatory changes, and global economic conditions.

Key Takeaways

• The Nifedipine API market is dominated by Indian and Chinese manufacturers, known for their large-scale production capabilities and competitive pricing.
• While the core Nifedipine compound is off-patent, innovation persists in process improvements, novel polymorphs, and advanced drug delivery formulations, leading to ongoing patent filings.
• Strict adherence to global GMP standards, comprehensive DMF submissions, and pharmacopoeial compliance are critical for API suppliers to access regulated markets.
• Market competition is fierce, with cost-efficiency, unwavering quality, supply chain reliability, and strong regulatory standing being the primary drivers of success.

Frequently Asked Questions

• What is the typical lead time for API orders from major Nifedipine suppliers? Lead times can vary but generally range from 4 to 12 weeks for standard orders from established suppliers, depending on order volume and current production schedules. Urgent or custom orders may incur higher costs and shorter lead times if feasible.

• How does the purity profile of Nifedipine API vary between manufacturers? Purity profiles are expected to meet pharmacopoeial standards (e.g., USP, Ph. Eur.), typically above 99%. However, specific impurity profiles, especially for trace impurities and related substances, can differ based on the synthesis route employed by each manufacturer. Regulatory filings (DMFs) detail these profiles.

• Are there specific Nifedipine API suppliers with FDA or EMA approval for manufacturing sites? Yes, major Nifedipine API suppliers serving regulated markets will have manufacturing facilities inspected and approved by regulatory bodies like the FDA and EMA. Companies maintain updated DMFs and often list these approvals in their technical documentation.

• What are the primary challenges for new entrants in the Nifedipine API market? New entrants face challenges in establishing large-scale, cost-effective manufacturing, achieving robust regulatory compliance and approvals (e.g., successful DMF filings and site inspections), building customer trust for supply chain reliability, and navigating existing patent landscapes.

• How do Nifedipine API prices compare between Indian and Chinese manufacturers? Generally, Chinese manufacturers may offer slightly more competitive pricing on high-volume orders due to scale and potentially lower manufacturing overheads. However, pricing is highly dependent on specific quality grades, regulatory certifications, and volume commitments, with Indian manufacturers also offering highly competitive rates, particularly for regulated markets where quality assurance is paramount.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website - Specific DMF guidance page if available, otherwise general DMF page] [2] European Medicines Agency. (n.d.). Active substances (APIs). Retrieved from [EMA Website - Specific API guidance page if available, otherwise general API page] [3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability (CEP). Retrieved from [EDQM Website - CEP section] [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH Website - Specific stability guideline (e.g., ICH Q1A(R2)) if readily linkable, otherwise general guidelines page] [5] United States Pharmacopeia. (n.d.). Pharmacopeial Information. Retrieved from [USP Website - Pharmacopeial Information section] [6] European Pharmacopoeia. (n.d.). Monographs. Retrieved from [European Pharmacopoeia Website - Monographs section]